In this issue:
LITESPARK-005: belzutifan bests everolimus in previously treated RCC
Perioperative nivolumab does not improve RFS in high-risk RCC
Pembrolizumab for papillary BCG-unresponsive high-risk NMIBC
Smoking doesn’t impact outcomes to front-line ICI therapy in RCC
Cabozantinib/nivolumab ± ipilimumab efficacious in advanced GU cancers
PIVOT-09 fails to demonstrate benefit to bempegaldesleukin/nivolumab in RCC
Novel antibody-drug conjugate active in pre-treated urothelial cancer
Predictive factors of nivolumab + ipilimumab efficacy in metastatic RCC
SUBDUE-1: sub-urothelial durvalumab safe in NMIBC
Please login below to download this issue (PDF)